The Boston Collaborative Drug Surveillance Program is a system of prospective monitoring of drug effects in hospitalized medical patients. Trained nurses and pharmacists are responsible for the most important link in the system–the day-to-day monitoring, recording, and compilation of data. This article describes the specialized functions of these nurse- and pharmacist-monitors.
Get full access to this article
View all access options for this article.
References
1.
SloneD.JickH.BordaI.: Drug Surveillance Utilising Nurse Monitors, Lancet2: 901–903, 1966.
2.
BordaI.SloneD.JickH.: Assessment of Adverse Reactions Within a Drug Surveillance Program, J. Am. Med. Assoc.205: 645–647, 1968.
3.
JickH.MiettinenO. S.ShapiroS.LewisG. P.SiskindV.SloneD.: Comprehensive Drug Surveillance, J. Am. Med. Assoc.213: 1455–1460, 1970.
4.
MillerR. R.: Drug Surveillance Utilizing Epidemiologic Methods: A Report from the Boston Collaborative Drug Surveillance Program, Am. J. Hosp. Pharm.30: 584–592, 1973.
5.
MillerR. R.: Comprehensive Prospective Drug Surveillance: A Report From the Boston Collaborative Drug Surveillance Program, Pharm. Weekbl.109: 461–481, 1974.
6.
JickH.: Drugs — Remarkably Non-toxic, N. Engl. J. Med.291: 824–828, 1974.
7.
SloneD.GaetanoL. F.LipworthL.ShapiroS.LewisG. P.JickH.: Computer Analysis of Epidemiologic Data on Effect of Drugs on Hospital Patients, Public Health Rep.84: 39–52, 1969.
8.
GaetanoL. F.MacLaughlinD. S.: Data Processing Aspects of the Boston Collaborative Drug Surveillance Program, Drug Info. Bull.5: 40–44, December 1971.
9.
JickH.: Computer Analysis of Epidemiologic Data About Drug Interactions in Hospital Patients, Drug Info. J.6: 72–80, January/June 1972.
10.
GaetanoL. F.MillerR. R.: Use of the Computer in Monitoring Drug Effects in Hospitalized Patients: A Report from the Boston Collaborative Drug Surveillance Program, J. Clin. Computing3: 310–316, 1974.
11.
ShapiroS.SloneD.LewisG. P.JickH.: The Epidemiology of Digoxin. A Study in Three Boston Hospitals, J. Chronic Dis.22: 361–371, 1969.
12.
GreenblattD. J.Koch-WeserJ.: Adverse Reactions to Spironolactone: A Report from the Boston Collaborative Drug Surveillance Program, J. Am. Med. Assoc.225: 40–43, 1973.
13.
GreenblattD. J.Koch-WeserJ.: Adverse Reactions to Propranolol in Hospitalized Medical Patients: A Report from the Boston Collaborative Drug Surveillance Program, Am. Heart J.86: 478–484, 1973.
14.
GreenblattD. J.Koch-WeserJ.: Adverse Reactions to β-Adrenergic Receptor Blocking Drugs: A Report from the Boston Collaborative Drug Surveillance Program, Drugs7: 118–129, 1974.
15.
LawsonD. H.: Adverse Reactions to Potassium Chloride: A Report from the Boston Collaborative Drug Surveillance Program, Q. J. Med.43: 433–440, 1974.
16.
Boston Collaborative Drug Surveillance Program: Adverse Reactions to the Tricyclic-Antidepressant Drugs, Lancet1: 529–531, 1972.
17.
GreenblattD. J.Koch-WeserJ.: Adverse Reactions to Intravenous Diazepam: A Report from the Boston Collaborative Drug Surveillance Program, Am. J. Med. Sci.266: 261–266, 1973.
18.
MillerR. R.: Clinical Effects of Pentazocine in Hospitalized Medical Patients: A Report from the Boston Collaborative Drug Surveillance Program, J. Clin. Pharmacol.15: 198–205, 1975.
19.
Boston Collaborative Drug Surveillance Program: Drug-Induced Deafness, J. Am. Med. Assoc.224: 515–516, 1973.
20.
Boston Collaborative Drug Surveillance Program: Drug-Induced Anaphylaxis, J. Am. Med. Assoc.224: 613–615, 1973.
21.
Boston Collaborative Drug Surveillance Program: Drug-Induced Extrapyramidal Symptoms, J. Am. Med. Assoc.224: 889–891, 1973.
22.
Boston Collaborative Drug Surveillance Program: Drug-Induced Convulsions, Lancet2: 677–679, 1972.
23.
ShapiroS.SloneD.SiskindV.LewisG. P.JickH.: Drug Rash with Ampicillin and Other Penicillins, Lancet2: 969–972, 1969.
24.
Boston Collaborative Surveillance Program: Ampicillin Rashes, Arch. Dermatol.107: 74–76, 1973.
25.
MillerR. R.: Hospital Admissions Due to Adverse Drug Reactions: A Report from the Boston Collaborative Drug Surveillance Program, Arch. Intern. Med.134: 219–223, 1974.
26.
ShapiroS.SloneD.LewisG. P.JickH.: Fatal Drug Reactions Among Medical Inpatients, J. Am. Med. Assoc.216: 467–472, 1971.
27.
JickH.SloneD.BordaI.ShapiroS.: Efficacy and Toxicity of Heparin in Relation to Age and Sex, N. Engl. J. Med.279: 284–286, 1968.
28.
Boston Collaborative Drug Surveillance Program: Clinical Depression of the Central Nervous System Due to Diazepam and Chlordiazepoxide in Relation to Cigarette Smoking and Age, N. Engl. J. Med.288: 277–280, 1973.
29.
MitchellA. A.: Relation of Body Weight and Insulin Dose to the Frequency of Hypoglycemia: A Report from the Boston Collaborative Drug Surveillance Program, J. Am. Med. Assoc.228: 192–194, 1974.
30.
Boston Collaborative Drug Surveillance Program: Acute Adverse Reactions to Prednisone in Relation to Dosage, Clin. Pharmacol. Ther.13: 694–698, 1972.
31.
SwettC.: Diphenylhydantoin Side Effects and Serum Albumin Levels: A Report from the Boston Collaborative Drug Surveillance Program, Clin. Pharmacol. Ther.14: 529–532, 1973.
32.
LewisG. P.JuskoW. J.BurkeC. W.GravesL.: Prednisone Side Effects and Serum Protein Levels, Lancet2: 778–781, 1971.
33.
GreenblattD. J.Koch-WeserJ.: Clinical Toxicity of Chlordiazepoxide and Diazepam in Relation to Serum Albumin Concentration: A Report from the Boston Collaborative Drug Surveillance Program, Eur. J. Clin. Pharmacol.7: 259–262, 1974.
34.
JickH.SloneD.WesterholmB.InmanW.VesseyM. P.ShapiroS.LewisG. P.WorcesterJ.: Venous Thromboembolic Disease and ABO Blood Type. A Cooperative Study, Lancet1: 539–542, 1969.
35.
Boston Collaborative Drug Surveillance Program: Relation Between Digoxin Arrhythmias and ABO Blood Groups, Circulation45: 352–357, 1972.
36.
MitchellA. A.: Relation Between Insulin-Induced Hypoglycemia and Serum Haptoglobin Level: A Report from the Boston Collaborative Drug Surveillance Program, Diabetes23: 151–153, 1974.
37.
Boston Collaborative Drug Surveillance Program: Decreased Clinical Efficacy of Propoxyphene in Cigarette Smokers, Clin. Pharmacol. Ther.14: 259–263, 1973.
38.
DuhmeD. W.GreenblattD. J.Koch-WeserJ.: Reduction of Digoxin Toxicity Associated with Measurement of Serum Levels: A Report from the Boston Collaborative Drug Surveillance Program, Ann. Intern. Med.80: 516–519, 1974.
39.
Boston Collaborative Drug Surveillance Program: Interaction Between Chloral Hydrate and Warfarin, N. Engl. J. Med.286: 53–55, 1972.
40.
Boston Collaborative Drug Surveillance Program: Tetracycline and Drug-Attributed Rises in Blood Urea Nitrogen. J. Am. Med. Assoc.220: 377–379, 1972.
41.
Boston Collaborative Drug Surveillance Program: Excess of Ampicillin Rashes Associated with Allopurinol or Hyperuricemia, N. Engl. J. Med.286: 505–507, 1972.
42.
Boston Collaborative Drug Surveillance Program: Allopurinol and Cytotoxic Drugs: Interaction in Relation to Bone Marrow Depression, J. Am. Med. Assoc.227: 1036–1040, 1974.
43.
SellersE. M.Koch-WeserJ.: Potentiation of Warfarin-Induced Hypoprothrombinemia by Chloral Hydrate, N. Engl. J. Med.283: 827–831, 1970.
